Sandra Ann Springer MD
Associate Professor of Medicine (AIDS); Director, Infectious Disease Outpatient Clinic, Veterans Administration Healthcare Services, Newington
Adherence Interventions for HIV+ prisoners with substance use disorders and mental illness, The use of Directly observed antiretroviral therapy (DAART); Buprenorphine/naloxone;extended-release naltrexone for alcohol and opioid dependence among HIV+ Criminal justice populations to improve retention in care post-release and suppress HIV Viral load.
1.. The effect of alcohol pharmacotherapy (extended-release naltrexone) in a double-blind placebo-controlled randominzed trial to assess effects on relapse to alcohol use and HIV biological endpoints (CD4 count, HIV-1 Viral Load) among HIV+ alcohol dependent released prisoners.
2. Using a randomized, placebo-controlled trial, HIV treatment, opioid treatment and HIV risk behavior outcomes are examined among HIV+ prisoners with opioid dependence who are treated with injectable naltrexone as they are released to the community.
3. HIV risk reduction among persons being released from correctional settings.
4. Improving linkages to care for HIV-infected released prisoners.
5. Identification and treatment of co-occurring mental illness among HIV+ released prisoners.
6. implementing Xr-ntx among opioid dependent persons in Ukraine.
7. Evalauting the effect of buprenorphine to improve linkage to care for HIV+ opioid dependent persons with criminal justice histories in Washington D.C.
Dr. Springer's research interests include improving adherence to antiretrovirals and drug treatment for HIV infected men and women with co-occurring substance use disorders and mental illness. Clinical research includes relapse prevention to opioid and alcohol use using substance dependence pharmacotherapies including buprenorphine and naltrexone among HIV+ released prisoners.
Extensive Research Description
She has received a 5 year K23 Career Development Award from the National Institute of Drug Abuse (NIDA) to study adherence interventions for HIV-infected opiate dependent released prisoners providing directly observed antiretroviral therapy and buprenorphine/naloxone treatment and its effects on relapse prevention as well as HIV clinical endpoints. Dr. Springer is also a CIRA- affiliated scientist. She has 2 R01s (NIAAA and NIDA) as principal investigator to evaluate the effectiveness of extended-release naltrexone to maintain HIV treatment outcomes via preventing relapse to alcohol and opioid use among HIV+ persons leaving the criminal justice system. She is a co-investigator on 2 R01s with PI Dr. Altice from NIDA (1) using buprenorphine to improve HIV treatment outcomes among opioid dependent persons with criminal justice histories in Washington D.C. and (2) implementing extended-release naltrexone for opioid dependent persons in Ukraine. She has a K02 independent scientist award from NIDA as well. Dr. Springer has expertise in the development and implementation of medication-assisted-therapy interventions involving HIV+, drug and alcohol dependent persons involved in the criminal justice setting.